Farmakeio Outsourcing LLC, Southlake, TX

Is Farmakeio Outsourcing LLC registered with the FDA as a 503B outsourcing facility?

Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Farmakeio Outsourcing LLC in Southlake, TX, first registered Dec 12, 2018 and most recently registered Dec 12, 2025.

Does Farmakeio Outsourcing LLC hold a Texas pharmacy license?

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The Delaware Division of Professional Regulation also lists nonresident license AD-0010102 for FarmaKeio Outsourcing, SOUTHLAKE, TX, status Active and license AD-0010080 for FarmaKeio Outsourcing, SOUTHLAKE, TX, status Closed, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301013558 for FarmaKeio Outsourcing LLC, Southlake, TX, status Active, as of Nov 10, 2026.

Has Farmakeio Outsourcing LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Jul 29, 2021) for Farmakeio Outsourcing LLC. Texas board disciplinary orders: not checked, because the board’s file flags orders only on a license, and no license matched this name and city.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Farmakeio Outsourcing LLC
Location
Southlake, TX
Type as FDA labels it
503B
FDA 503B list
Listed as Farmakeio Outsourcing LLC
Form 483s on FDA’s actions page
3
Warning letters on FDA’s actions page
1
Latest action on that page
Sep 5, 2025
FDA Data Dashboard inspections
2 inspections: 2 OAI; 3 published Form 483s
Form 483 text on this page
3 Form 483s, 15 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Farmakeio Outsourcing LLC, a 503B facility, with 5 dated actions.

Document
Sep 5, 2025Form 483483 Issued 09/05/2025fda.gov
Jan 31, 2023Regulatory meetingRegulatory Meeting Held 01/31/2023Not linked by FDA
Jun 14, 2022Amended Form 483Amended 483 Issued 6/14/2022FDA copy (archived)
Jul 29, 2021Warning letterWarning Letter (07/29/2021)FDA copy (archived)
Oct 30, 2019Form 483483 Issued 10/30/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists FARMAKEIO OUTSOURCING LLC, Southlake, TX (FEI number 3014982757), matched to this page by exact name, city and state. It lists 2 inspections: 2 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jun 10, 2022Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30149827571171544
Oct 30, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30149827571114855

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 15 numbered observations in all, across 3 inspections ending Oct 30, 2019 to Sep 5, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 18, 2025 to Sep 5, 2025: 5 observations

Firm on the cover
FARMAKEIO OUTSOURCING LLC, 920 S Kimball Ave Ste 100, Southlake, TX 76092-9019
FEI number
3014982757
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, 503B list, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

A. Your firm failed to adequately investigate and initiate corrective and preventive actions for CAPA #, CAPA-2025-0002 dated 03 Apr 2025, which documents metal shavings being found during Testosterone/Triamcinolone Acetonide granulation resulting from a worn impeller shaft seal and metal fit ring. Your firm failed to identify and or confirm how long the shaft and ring had been worn and or expand the investigation beyond immediately manufactured batches, and into other manufactured finished sterile implantable distributed pellets, e.g., Testosterone Pellet (Product Strengths: 200mg, Lot 3203, Expi.ty 2/17/202026; 87.5mg, Lot 3193, Expi1y 2/17/2026; 62.5mg, Lot 3180, Expiry 2/17/2026; & 50mg, Lot 3179, Expi.ty 2/17/2026) from Testosterone Granulation Lot <Redacted B4> Expiry 2/17/2026. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically,

A. During a review of your firm's batch record for Product ID# 364, Testosterone/ Triamcinolone Acetonide Pellet (200mg/40mcg), Lot# 3131, including laboratory test chromatograms, unknown/unidentified peaks were found during sampling testing prior to and following <Redacted B4> sterilization. Your firm's management reported they are aware of the unknown peaks and at the time of this inspection is working with a contract testing laboratory to identify and determine the pharmacological activity of the foreign peaks for the Testosterone/Triamcinolone Acetonide pellets. Your firm released and distributed this lot and continued producing and distributing more lots of this pellet product without identifying the unknowns.

B. Testosterone/Triamcinolone Acetonide Granulation 95%/0.02 % Chemical Lot <Redacted B4> Expiry 1/29/2026, Qty. <Redacted B4> and Lot <Redacted B4> Expiry 2/03/2026, Qty. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Each batch of controlled-release dosage form drug product is not laboratory tested to determine conformance to the specifications for the rate of release for each active ingredient.

Specifically, your firm failed to require or perform dissolution testing on each batch of controlled-release dosage form drug product. The drug product is not laboratory tested to determine conformance to the specifications at a rate of release for each active ingredient that is reproducible. At the time of this FDA inspection, your firm failed to adequately define a dissolution specification for the following pellet product families.

A. Testosterone Regular Release Pellet (Contains no Ethylcellulose excipient); Product Strengths: 200mg & 50mg; BUD 365 days.

B. Testosterone Pellet (Contains Ethylcellulose excipient); Product Strengths: 200mg, 100mg, 87.5mg, 62.5mg, 50mg, 37.5mg, 25mg, & 12.5mg; BUD 365 days.

C. Testosterone/Triamcinolone Acetonide Pellet; Product Strengths: 200mg/40mcg, 100mg/20mcg, 87.5mg/17.5mcg, 62.5mg/12.5 mcg, 50mg/10mcg, 37.5mg/7.5mcg, 25mg/5mcg, & 12.5mg/2.5mcg; BUD 365 days.

D. Estradiol Pellet; Product Strnngths: 25mg, 20mg, 18mg, 15mg, 12.5mg, 10mg, & 6mg; BUD 365 days.

Observation 4

Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design and of adequate size to facilitate operations for its intended use.

Specifically,

A. Your firm's <Redacted B4> Systems, <Redacted B4> Metal detection System qualification failed to show the equipment is adequately designed and sized to facilitate operations for its intended use. During a review of your firm's <Redacted B4>, Pharmaceutical Metal Detector Performance Qualification Manual, Approval Date 5/192025, the PQ acceptance criteria was found inadequate, and failed to require specifications for the test equipment and materials. For example, within Section 7.2.2, Acceptance Criteria, your firm failed to quantify (based on <Redacted B4> acceptance and reject allowances for <Redacted B4>, and <Redacted B4> tablets or test samples. Additionally, in Section 7.2.3, Test Equipment and Materials, your firm failed to quantify how many total samples shall be used for each type (i.e. <Redacted B4> and <Redacted B4> as part of the production equipment qualification. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Routine calibration and checking of automatic and electronic equipment is not performed according to a written program designed to assure proper performance.

Specifically, during a review of your firm's batch record for Testosterone/Triamcinolone Acetonide Pellet 200mg/40mcg, Lot 3468, Expiry 7/23/2026, Sections 2.3.1.3 -2.3.1.5, document pellets being processed through the <Redacted B4> Systems, <Redacted B4> Metal detection System. Section 2.3.1.5, states <Redacted B4> ". Your firm's batch record fail to define and document the type of each sample shall be used, number of control samples, and the frequency during pellet processing to ensure proper performance.

Inspection Jun 1, 2022 to Jun 10, 2022: 7 observations

Firm on the cover
FARMAKEIO OUTSOURCING LLC, 920 S Kimball Ave Ste 100, Southlake, TX 76092 -9019
FEI number
3014982757
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.

Specifically,

Your Phaimacist/Quality Director released lots of hormone replacement pellets for distribution without laboratory testing data to demonstrate that established final specifications such as sterility, potency and endotoxin limits were met prior to release for distribution. For example,

• Testosterone/Triamcinolone Acetonide Pellet 200mg/40mcg, Lot <Redacted B4> BUD: 2023-05-04 shipped and delivered to a customer in <Redacted B4>.

DEstriadol Pellet 25mg, Lot# <Redacted B4> BUD: 2023-05-12 shipped and delivered to a customer in <Redacted B4> .......... In addition, your firm's SOP entitled, "Finished Product Release Testing" SOP QMS-3015 Effective 06/01/2019 is silent regarding this practice of releasing finished product for distribution in absence of complete testing data.

Observation 2

Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.

Specifically,

Your firm's places <Redacted B4> beyond use date/expiration date on your Testosterone pellets containing Triamcinolone in various strengths however, your bracketed stability data shows that the Triamcinolone was consistently subpotent when tested initially and at the following time points: and <Redacted B4>

AMENDM ENT 1

Triamcinolone in various strengths however, your bracketed stability data shows that the Triamcinolone was consistently subpotent when tested initially and at the following time points: and --------

Observation 3

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically,

Your firm's current potency specification of <Redacted B4> set for Triamcinolone instead of the scientifically recognized <Redacted B4> is not scientifically sound or appropriate which allowed drug products containing sub potent or super potent Triamcione to be released and distributed to patients. From 6/1/2021 to time of inspection there were at least <Redacted B4> of Testosterone/Triamcinolone pellets where Triamcinolone did not meet the standard potency specificaton of <Redacted B4>.

Observation 4

Written procedures are not drafted, reviewed and approved by the appropriate organizational units.

Specifically,

Your firm failed to document the changes to the quantity of Triamcinolone acetonide within the granulation batch records for Testosterone/Triamcinolone <Redacted B4> for the following Lots: <Redacted B4> without appropriate review and approval by the Quality Unit.

Observation 5

The labels of your outsourcing facility's drug products are deficient.

Specifically,

AMENDMENT 1

The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A). All your drug products have a National Drug Code (NDC) which is currently not listed on all your compounded drug product labels. At time of inspection, Testosteroneffriamcinolone Pellet 200mg/40mcg is the only drug that lists the NDC on its container/product label.

Observation 6

The container labels of your outsourcing facility's drug products are deficient.

Specifically,

The containers of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(B). For example, your container labels do not include the following information:

• Directions for Use -Dosage form and route of administration per 503B(a)(l 0)(B)(iii).

Observation 7

Processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

a) Your firm's ISO 7, ISO 8 classified areas are certified by a third-patty vendor on <Redacted B4> basis however, microbial testing was not performed during the last two room certifications to ensure that the classified areas used to prepare, form, package and label your hormone replacement pellets meet microbial specifications of their intended classifications.

b) Your firm conducts environmental monitoring of the ISO 7 areas dedicated to manufacturing, pelletizing, packaging and labeling of your drug products however, it is being performed inadequately. For example, non-viable monitoring is not performed during operations, surfaces are disinfected to sampling and glove monitoring is conducted on <Redacted B4> basis.

AMENDMENT 1

Inspection Oct 22, 2019 to Oct 30, 2019: 3 observations

Firm on the cover
FARMAKEIO OUTSOURCING LLC, 920 S Kimball Ave Ste 100, Southlake, TX 76092-9019
FEI number
3014982757
Establishment type on the cover
OUTSOURCING FAC ILITY
FDA district office on the cover
4040 North Central Expressway, Suite 300 Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(l O)(A). Specifically, the statement, "This is a compounded drug," is not on your drug product labels.

• Labels for the following drug products do not contain this statement include:

Drug Name Drug Form Drug Strength 1ESIOSIB«>NE/1RIAMCINOIONE PB.I.ET llllNG/lfNOO TESTOSTERONE/TRIAMCINOLONE PELLET 200MG/40MCG TESTOSTERONE/TRIAMCINOLONE PELLET 87.5MG/17.5MCG TESTOSTERONE/TRIAMCINOLONE PELLET 62.5MG/12.5MCG TESTOSTERONE/TRIAMCINOLONE PELLET 50MG/10MCG TESTOSTERONE/TRIAMCINOLONE PELLET 37.5MG/7.5MCG

TESTOSTERONE/TRIAMCINOLONE PELLET 25MG/5MCG TESTOSTERONE/TRIAMCINOLONE PELLET 12MG/2.5MCG ESTRADIOL PELLET 6MG ESTRADIOL PELLET 10MG

ESTRADIOL PELLET 12.5MG

ESTRADIOL PELLET 15MG ESTRADIOL PELLET 18MG ESTRADIOL PELLET 20MG ESTRADIOL PELLET 25MG TESTOSTERONE PELLET 12.5MG TESTOSTERONE PELLET 25MG

TESTOSTERONE PELLET 37.5MG TESTOSTERONE PELLET 50MG TESTOSTERONE PELLET 62.5MG TESTOSTERONE PELLET 87.5MG TESTOSTERONE PELLET 100MG TESTOSTERONE PELLET 200MG

Observation 2

You compound drugs that are essentially a copy of one or more approved drugs within the meaning of sections 503B(a)(S) and 503B(d)(2). Specifical1y, a) you compound a drug product that is identical or nearly identical to an approved drug that is not on the drug shortage list in effect under section 506E at the time of compounding, disttibution, and dispensing; or b) are not identical or nearly identical to an approved drug, but contain a bulk drug substance that is also a component of an approved drug, and for which there is no change that produces for an individual patient a clinical difference, as determined by the prescribing practitioner, between the compounded drug and the comparable approved drug.

Examples of compounded drug products that are essentially a copy of one or more approved drugs include:

• Testosterone Pellets in 12.5 mg, 25 mg, 37.5 mg, 50 mg, 62.5 mg, 87.5 mg, 100 mg, and 200 mg strengths.

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, you are not monitoring the environmental conditions for each batch of product you manufacture.

N~r k Examples of compounded drug products lots that were not environmentally monitored during production:

• BR, Lot 176, and BR, Lot 178

State board of pharmacy records

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.

What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
AD-0010102Outsourcing Facility-DistributorFarmaKeio OutsourcingSOUTHLAKE, TXActive
AD-0010080Outsourcing Facility-DistributorFarmaKeio OutsourcingSOUTHLAKE, TXClosed

Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).

LicenseType as the board gives itName on the board recordLocationStatus
5301013558PharmacyFarmaKeio Outsourcing LLCSouthlake, TXActive

FDA’s 503B list

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.